Roivant Sciences (ROIV) CFO awarded 60,644 RSUs and 84,026 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Pulik Richard reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences CFO Richard Pulik received equity compensation on April 20, 2026. He was granted 60,644 Common Shares as restricted stock units and now holds 297,511 Common Shares directly. He also received 84,026 stock options to buy Common Shares at $29.08 per share, expiring in 2036.
The RSUs vest 25% one year after April 20, 2026, with the rest in twelve equal quarterly installments. The options vest 25% one year after that date, then in thirty-six equal monthly installments, all subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Pulik Richard
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 84,026 | $0.00 | -- |
| Grant/Award | Common Shares | 60,644 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 84,026 shares (Direct, null);
Common Shares — 297,511 shares (Direct, null)
Footnotes (1)
- Reflects an award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2026. These RSUs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in twelve (12) successive equal quarterly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through the applicable vesting date. Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through the applicable vesting date.
Key Figures
RSU grant: 60,644 Common Shares
Options granted: 84,026 options
Option exercise price: $29.08 per share
+5 more
8 metrics
RSU grant
60,644 Common Shares
Restricted stock units granted April 20, 2026
Options granted
84,026 options
Stock options on Common Shares granted April 20, 2026
Option exercise price
$29.08 per share
Stock option strike price
Shares held after grant
297,511 Common Shares
Direct holdings following RSU award
Option expiration
2036-04-19
Expiration date of stock options
RSU initial vesting
25% after 1 year
First tranche of RSU vesting from April 20, 2026
RSU remaining vesting pattern
12 equal quarterly installments
Remaining RSU vesting after first anniversary
Option vesting pattern
25% after 1 year, then 36 monthly
Stock option vesting schedule from April 20, 2026
Key Terms
restricted stock units ("RSUs"), vesting commencement date, stock options, exercise price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Reflects an award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting commencement date financial
"with a vesting commencement date of April 20, 2026. These RSUs vest (i) 25% on the first anniversary..."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
stock options financial
"Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"stock options to purchase Common Shares with a vesting commencement date... with a conversion or exercise price of 29.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"subject to the reporting person's continuous service through the applicable vesting date."
FAQ
What equity awards did Roivant Sciences (ROIV) CFO Richard Pulik receive?
Roivant Sciences CFO Richard Pulik received 60,644 RSUs and 84,026 stock options on Common Shares. The options have a $29.08 exercise price. These awards represent standard compensation grants rather than open-market purchases or sales.
How do the new RSUs for Roivant Sciences (ROIV) CFO vest?
The 60,644 RSUs for Roivant Sciences CFO vest over time. 25% vest one year after April 20, 2026. The remaining RSUs vest in twelve equal quarterly installments, conditioned on his continuous service with the company through each vesting date.
What are the terms of the new Roivant Sciences (ROIV) stock options granted to the CFO?
Richard Pulik’s 84,026 stock options allow him to buy Common Shares at $29.08 per share. 25% vest one year after April 20, 2026, with the rest vesting in thirty-six equal monthly installments until their expiration in 2036.
Are the recent Roivant Sciences (ROIV) CFO transactions open-market buys or routine grants?
The filing shows grant/award acquisitions, not open-market trades. Both the 60,644 RSUs and 84,026 stock options were awarded as compensation, with no purchase price paid and vesting tied to his continued employment with Roivant Sciences.